Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Precigen, Inc. PGEN
$1.05
-$0.08 (-7.89%)
На 18:01, 12 мая 2023
+471.43%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
320631175.00000000
-
week52high
2.90
-
week52low
0.81
-
Revenue
26909000
-
P/E TTM
-3
-
Beta
1.95051900
-
EPS
-0.41000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L. lactis is a food-grade bacterium. Additionally, it provides RheoSwitch, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 09 авг 2022 г. |
| Stifel | Buy | 25 февр 2021 г. | |
| Wells Fargo | Overweight | 22 февр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 16 дек 2020 г. |
| H.C. Wainwright | Buy | Buy | 08 мая 2020 г. |
| JMP Securities | Market Outperform | Market Outperform | 14 ноя 2022 г. |
| Cantor Fitzgerald | Overweight | 18 ноя 2022 г. | |
| Cantor Fitzgerald | Overweight | Overweight | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| KIRK RANDAL J | A | 31129164 | 11428571 | 27 янв 2023 г. |
| Shah Rutul R | A | 62037 | 9142 | 27 янв 2023 г. |
| Perez Jeffrey Thomas | A | 381012 | 28571 | 27 янв 2023 г. |
| Sabzevari Helen | A | 937613 | 22857 | 27 янв 2023 г. |
| Thomasian Harry Jr. | A | 84961 | 28571 | 27 янв 2023 г. |
| KIRK RANDAL J | D | 0 | 3443 | 04 янв 2023 г. |
| KIRK RANDAL J | A | 19700593 | 3443 | 04 янв 2023 г. |
| Sabzevari Helen | D | 0 | 17665 | 04 янв 2023 г. |
| Sabzevari Helen | A | 914756 | 17665 | 04 янв 2023 г. |
| Lehr Donald P. | D | 0 | 18939 | 04 янв 2023 г. |
Новостная лента
3 Penny Stocks To Buy According To Insider Bets Up To $25 Million
PennyStocks
06 февр 2023 г. в 15:53
Penny stocks to buy according to insider trades this quarter. The post 3 Penny Stocks To Buy According To Insider Bets Up To $25 Million appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
27 янв 2023 г. в 13:33
Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
PRNewsWire
19 дек 2022 г. в 16:05
GERMANTOWN, Md. , Dec. 19, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 41st Annual J.P.
Precigen, Inc. (PGEN) Q3 2022 Earnings Call Transcript
Seeking Alpha
09 ноя 2022 г. в 22:59
Precigen, Inc. (NASDAQ:PGEN ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Ben Burnett - Stifel Arthur He - H.C. Wainwright Jennifer Kim - Cantor Fitzgerald Operator Good day, and welcome to the Precigen Third Quarter 2022 Financial Results Conference Call.
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
09 ноя 2022 г. в 20:19
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of -140% and 67.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?